Registered in Tai-Chung City with capital of NT$2 millions.

Moved to Taipei Chong shan N. Road office and increased capital to NT$18 millions. Entered co-developed agreement with Genovate Biotechnology. Entered distribution agreement with Dupont Pharmaceuticals.

Entered distribution agreement with 3M Pharmaceuticals. Increased capital to NT$22 millions.

Signed exclusive distribution agreement with Biogen Idec, a US company for conducting the first biologics clinical trial.

Changed ownership to Limited Company with the same capital size.

Signed exclusive distribution agreement with Vitrolife,a Swedish company for its lung transplant preservative.

Acquired Apex Pharma and increase capital size to NT$100M.

Distributed SAM Medical Products for emergency care.

Distribute 3 River Pharmaceuticals long acting Amphotericin.

Entered co-developing agreement with Raptor Therapeutics to conduct Convivia phase II b trial for future marketing and OEM.

Entered exclusive agreement with AMDL Diagnostics Inc. for DR-70® tumor marker ELISA test for Taiwan.

Entered exclusive agreement with Baxter Healthcare for Anti-adhesion medical device.

Entered technology transfer agreement with AMDL Inc. to manufacture DR-70® in Taiwan and supply to Asia-Pacific countries.

Moved to Current Nei-hu office and increased capital to NT$130 millions. Granted DR-70® Taiwan manufacturing license. Entered distribution agreement with iStat for its Cervi-M DNA Methylation test for Cervical Cancer. Increased capital to NT$170 millions. First export Taiwan version DR-70 to India.

Received Taiwan FDA award as Good Distribution Practice company.

Certified by TRACE and received clearance of anti bribery Compliance Solutions.

Received ISO13495:2003 Medical Device Certification by SGS.

Establishing Uni Pharma in-house laboratory for new neurological bio-markers R&D and anti-cancer drug blood concentration monitoring test.